As of today (2024-05-27), Genfit's share price is $2.95.
Genfit's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Genfit's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Genfit's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Genfit's highest Price-to-Free-Cash-Flow Ratio was 2.50. The lowest was 1.72. And the median was 2.01.
GNFTF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.53 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 22.50% per year.
During the past 13 years, Genfit's highest 3-Year average Free Cash Flow per Share Growth Rate was 22.50% per year. The lowest was -131.30% per year. And the median was -7.90% per year.
Genfit Price-to-Free-Cash-Flow Historical Data
The historical data trend for Genfit's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genfit's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Genfit's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genfit's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genfit's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genfit's Price-to-Free-Cash-Flow falls into.
Genfit Price-to-Free-Cash-Flow Calculation
Genfit's Price-to-Free-Cash-Flow ratio for today is calculated as
Genfit's Share Price of today is $2.95. Genfit's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Genfit Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Genfit's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNFTF has been successfully added to your 